INS and diabetes mellitus: Therefore, sitagliptin represents the introduction of an expensive brand name drug, considered a moderately novel diabetes treatment, into a market that contained a large number of both generic and brand name treatment options, plus multiple, highly expensive, insulin alternatives [14].